---
title: Distinguish essential tremor from Parkinsons
nct_id: NCT06378619
status: RECRUITING
sponsor: "Consorci Sanitari de l'Alt Penedès i Garraf"
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06378619"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06378619"
last_fetched: "2026-05-10T14:04:07.216Z"
source: "Parkinson's Pathways (curated)"
---
# Distinguish essential tremor from Parkinsons

**Goal (in five words):** Distinguish essential tremor from Parkinsons

**Official Title:** Machine Learning Analysis Of The Tapping Test And The Archimedean Spiral For The Differential Diagnosis Of Essential Tremor And Parkinson's Disease.

**Trial ID:** [NCT06378619](https://clinicaltrials.gov/study/NCT06378619)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Consorci Sanitari de l'Alt Penedès i Garraf
- **Target Enrollment:** 110 participants
- **Start Date:** 2024-07-15
- **Completion Date:** 2026-07
- **Conditions:** Tremor, Essential Tremor, Parkinson Disease
- **Interventions:** Tapping Test, Archimedes Spiral
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The goal is to help neurologists tell Parkinson's tremor from essential tremor more reliably using simple hand tests and computer analysis. People will do a finger tapping test and draw an Archimedean spiral while researchers measure speed, rhythm, tremor amplitude and tracing stability, then machine learning looks for patterns like slowed, irregular tapping with position-dependent tremor in Parkinson's versus the more regular kinetic tremor of essential tremor. The trial is enrolling people aged 45 to 79 who either have early-stage Parkinson's tremor with bradykinesia and Hoehn and Yahr stage 1 to 2, or have essential tremor diagnosed for at least 3 years with no bradykinesia. Individuals on antipsychotics, antidepressants, dopaminergic agonists or primidone, those with dyskinesias, severe tremor that prevents tracing, significant neuropathy, cognitive or affective problems, alcoholism, dystonia, prior stroke, or conflicting trial participation are excluded.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 79 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Possibility to collaborate in the necessary evaluations.
* Follow-up in the specialized consultation of Movement Disorders at the Neurology Service of Hospital Sant Camil-Consorci Sanitari Alt Penedes i Garraf.
* Legal capacity to provide informed consent.
* Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.
* Participant with criteria from Group 1 or 2:

Group 1:

* Confirmed diagnosis of tremor due to Parkinson's disease, clinically established, based on the diagnostic criteria of the Movement Disorders Society, and additionally:
* Tremor associated with bradykinesia of any duration.
* Confirmatory clinical diagnosis of tremor due to Parkinson's disease (stages 1 to 2 of Hoehn and Yahr) by the neurologist responsible for the participant's follow-up.

Group 2:

* Confirmed diagnosis of essential tremor, based on the criteria of the Movement Disorders Society, and additionally:
* Positional tremor plus kinetic and/or resting tremor with follow-up in outpatient neurology consultations for at least 3 years without a change in diagnosis.
* Absence of bradykinesia.

Exclusion Criteria:

* Patients undergoing treatment with antipsychotics or antidepressants.
* Patients with Parkinson's disease and dyskinesias.
* Patients undergoing treatment with dopaminergic agonists or primidone.
* Tremor of such severity that it prevents continuous tracing, at the investigator's discretion.
* Cognitive or affective pathology that limits the ability to collaborate with the study procedures.
* Participation in another clinical study involving an intervention, procedure, or visit frequency that is incompatible with the present study.
* Participants diagnosed with any of the following conditions:

Alcoholism of sufficient intensity to influence handwriting or cause neuropathy, at the investigator's discretion. Peripheral neuropathy of any cause. Dystonias. Previous stroke.
```

## Locations (1)

- Hospital Sant Camil-Consorci Sanitari Alt'Pènedes i Garraf, Barcelona, Catalonia, Spain _(41.3888, 2.1590)_
  - José Luis Camacho, MD — (CONTACT) — +34 938960025 — jlcamacho@csapg.cat
  - Noemí Casaponsa — (CONTACT) — +34 938960025 — recerca@csapg.cat
  - José Luis Camacho, MD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- José Luis Camacho, MD — (CONTACT) — +34 938960025 — jlcamacho@csapg.cat
- Noemí Casaponsa — (CONTACT) — +34 938960025 — recerca@csapg.cat

---

*Canonical: https://parkinsonspathways.com/trial/NCT06378619*  
*HTML version: https://parkinsonspathways.com/trial/NCT06378619*  
*Source data: https://clinicaltrials.gov/study/NCT06378619*